Major R&D Pipeline: 3ADCs
ENHERTU®: Gastric cancer
DESTINY-Gastric02 study (HER2+, 2L, Ph2, US/Europe): TLR obtained in June
Filing strategy currently under discussion with European health authority in FY2021 2H.
DESTINY-Gastric04 study (HER2+, 2L, Ph3, global): First patient dosed in June
Ph3 study with overall survival as primary endpoint in patients with 2nd line metastatic gastric cancer
➤ The study data is required for filing in Japan
DESTINY-Gastric02 study design
2L HER2 positive
metastatic gastric
cancer
Endpoints: ORR
ENHERTUⓇ
as well as other endpoints
DESTINY-Gastric04 study design
2L HER2 positive
metastatic gastric
cancer
Endpoints: OS as well as other endpoints
ORR: objective response rate, OS: overall survival, TLR: top line results
ENHERTUⓇ
Randomize
1:1
Ramucirumab
+ Paclitaxel
Daiichi-Sankyo
17View entire presentation